Solbec mesothelioma trial shows promise
03 June, 2004 by Graeme O'NeillThe news from a pre-clinical trial of Perth biopharma Solbec Pharmaceuticals' (ASX:SBP) lead anti-cancer compound SBO002 could hardly be more positive.
QLD 'kissing disease' vaccine on the way
02 June, 2004 by Graeme O'NeillResearchers at the Queensland Institute for Medical Research (QIMR) in Brisbane hope to begin human trials late this year of a vaccine that could prevent three different forms of cancer associated with infection by Epstein-Barr virus.
Cerylid, Kinacia to merge
02 June, 2004 by Melissa TrudingerMelbourne biotech Cerylid Biosciences has acquired fellow unlisted biotech Kinacia in a merger that finally puts an end to months of rumour.
Regenera closes oversubscribed in tough market
02 June, 2004 by Renate KrellePerth-based opthamology specialist Regenera has prevailed in an increasingly tough IPO market, closing its IPO today AUD$2 million oversubscribed, having raised in excess of AUD$10 million.
Psivida takes over UK subsidiary
02 June, 2004 by Graeme O'NeillPerth-based nano-biotech company Psivida (ASX:PSD) has acquired 100 per cent ownership of its UK subsidiary PsiMedica in a AUD$57.8 million deal aimed at accelerating development of its BioSilicon technology.
News: Glaxo award winner getting more out of LIF
02 June, 2004 by Melissa TrudingerProf Doug Hilton, a researcher at the Walter and Eliza Hall Institute in Melbourne, has been awarded this year's GlaxoSmithKline award for research excellence, for his work on cell signalling.
News: Shark and crustacean extracts may fight osteoarthritis
02 June, 2004 by Graeme O'NeillCan an extract of shark cartilage and crustacean shells alleviate the pain and inflammation of symptoms of osteoarthritis, the most common disease of aging? It’s a multi-billion question that medical science has shown little interest in answering, according to Melbourne rheumatologist and osteoarthritis expert Dr Daniel Lewis.
Australia's rich agribiotech harvest
01 June, 2004 by Graeme O'NeillFrom wine to wheat to mouse plagues, Australian life scientists are nothing if not creative in agricultural biotech, writes Graeme O'Neill.
New BioSilicon patents granted
01 June, 2004 by Graeme O'NeillThe patents keep rolling in for Perth biotech-nanotech company Psivida (ASX:PSD), which has announced that the European Patent Office (EPO) has granted its UK operating subsidiary pSiMedica another patent on biodegradable silicon implants for drug delivery.
Vision Biosystems' tissue processor 'hits the ground running'
01 June, 2004 by Melissa TrudingerMelbourne-based equipment manufacturer Vision Biosystems, part of the Vision Systems group (ASX:VSL), has launched its Peloris tissue processor in Australia, and plans to launch the instrument in international markets as well.
Prana shareholders approve US capital raising
01 June, 2004 by Renate KrellePrana (ASX: PBT; NASDAQ: PRAN) shareholders today gave the stamp of approval to the company's AUD$28 million capital raising, voting in favour of the sale to US institutional investors of 3 million ADRs at US$5 per ADR.
Roche's anaemia therapy trial gets underway worldwide
01 June, 2004 by Graeme O'NeillSwiss pharmaceutical giant Roche has begun a massive, 484-centre Phase III trial of its new drug for anaemia associated with chronic kidney disease.
Eiffel's Nasdaq view improves as ADR completed
01 June, 2004 by Melissa TrudingerEiffel Technologies (ASX:EIF) has established a Level 1 American Depository Receipt (ADR) program in a first step towards a possible international listing for the company.
BresaGen merger still looks likely
01 June, 2004 by Melissa Trudinger and Renate KrelleThe merger of BresaGen's US-based cell therapy division with San Diego stem cell company Cythera looks like it will go ahead, after the two companies executed the merger agreement last week.
Biosignal animal studies show efficacy
31 May, 2004 by Melissa TrudingerBiosignal (ASX:BOS) has confirmed the efficacy of its furanone molecules in preventing bacterial colonisation of contact lenses in animal studies, paving the way for more extensive human studies.
